Blood-retina barrier permeability in diabetes during acute ACE-inhibition

Acta Ophthalmol (Copenh). 1991 Oct;69(5):581-5. doi: 10.1111/j.1755-3768.1991.tb04843.x.

Abstract

We assessed the acute effect of ACE-inhibition (captopril) on blood-retina barrier (BRB) permeability in 10 hypertensive insulin-dependent diabetic patients with background retinopathy in a double-masked placebo controlled cross-over study. All patients underwent ophthalmological examination, fundus photography, fluorescein angiography, vitreous fluorometry, and continuous blood pressure recording within 3 h of the drug/placebo administration. The decrease in mean arterial blood pressure, from placebo treatment 149/92 +/- 17/7 to captopril treatment 132/83 +/- 14/7 mmHg (mean +/- SD), P less than 0.01 was not accompanied by a significant decrease in BRB permeability, which was 2.51 (1.24-9.15) with placebo and 3.02 (1.25-13.93).10(-7) cm/s during captopril treatment (geometric mean and-range), NS. Our study suggests that abnormal leakage through the BRB in hypertensive insulin-dependent diabetic patients with background retinopathy is caused predominantly by structural changes in the retinal vessels whereas hydrostatic forces play a minor role.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Albuminuria / urine
  • Blood-Retinal Barrier*
  • Captopril / pharmacokinetics*
  • Cell Membrane Permeability
  • Diabetes Mellitus, Type 1 / metabolism*
  • Diabetic Retinopathy / metabolism*
  • Double-Blind Method
  • Female
  • Fluorescein
  • Fluorescein Angiography
  • Fluoresceins / pharmacokinetics
  • Fluorophotometry
  • Humans
  • Hypertension / metabolism*
  • Hypertension / physiopathology
  • Male
  • Middle Aged

Substances

  • Fluoresceins
  • Captopril
  • Fluorescein